Imperial College London

Dr Jonathan Underwood

Faculty of MedicineDepartment of Infectious Disease

Honorary Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)20 3312 1466jonathan.underwood Website CV

 
 
//

Location

 

Winston Churchill WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Underwood:2016:10.1007/s11904-016-0324-x,
author = {Underwood, J and Winston, A},
doi = {10.1007/s11904-016-0324-x},
journal = {Current HIV/AIDS Reports},
pages = {235--240},
title = {Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals},
url = {http://dx.doi.org/10.1007/s11904-016-0324-x},
volume = {13},
year = {2016}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Antiretroviral therapy has revolutionised the treatment for people living with HIV (PLWH). Where antiretroviral coverage is high, the treatment paradigm for HIV-disease is now one of managing the long-term consequences of the virus and its treatment rather than the consequences of untreated HIV-disease such as immunosuppression and opportunistic infections. One such long-term consequence is HIV-associated cognitive impairment which is reported to occur in up to 50 % of treated PLWH and has been associated with poorer outcomes. Given the ageing cohort and increased frequency of comorbidities, the prevalence of symptomatic cognitive impairment may increase with time. High quality evidence for management strategies including screening, diagnosis and treatment of HIV-associated cognitive impairment are lacking and in general guidelines are based on best clinical practice. In this article, we assessed recent guidelines concerning the management of HIV-associated cognitive impairment by performing a systematic review of the MEDLINE database using PubMed. We report that, in general, guidelines from around the world regarding the management of HIV-associated cognitive impairment are converging. Screening is generally not recommended in asymptomatic PLWH. Diagnosis of HIV-associated cognitive impairment should be made only after a comprehensive assessment and exclusion of other potential causes. Antiretroviral therapy forms the cornerstone of management of HIV-associated cognitive impairment and should be guided by plasma and cerebrospinal fluid (CSF) genotype(s).
AU - Underwood,J
AU - Winston,A
DO - 10.1007/s11904-016-0324-x
EP - 240
PY - 2016///
SN - 1548-3576
SP - 235
TI - Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals
T2 - Current HIV/AIDS Reports
UR - http://dx.doi.org/10.1007/s11904-016-0324-x
UR - http://hdl.handle.net/10044/1/34515
VL - 13
ER -